Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 3
Submit an article Journal homepage
90
Views
19
CrossRef citations to date
0
Altmetric
Letter to the Editor

Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease

Angelo Michele Carella Division of Hematology I, Department of Onco-Hematology, Azienda Ospedaliera Universitaria San Martino, Genova, ItalyCorrespondence[email protected]
,
Samantha Biasco Division of Hematology I, Department of Onco-Hematology, Azienda Ospedaliera Universitaria San Martino, Genova, Italy
,
Sandro Nati Division of Hematology I, Department of Onco-Hematology, Azienda Ospedaliera Universitaria San Martino, Genova, Italy
,
Angela Congiu Division of Hematology I, Department of Onco-Hematology, Azienda Ospedaliera Universitaria San Martino, Genova, Italy
&
Enrica Lerma Division of Hematology I, Department of Onco-Hematology, Azienda Ospedaliera Universitaria San Martino, Genova, Italy
Pages 623-624 | Received 16 Oct 2006, Accepted 30 Oct 2006, Published online: 01 Jul 2009

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

T Schroeder, R Haas & G Kobbe. (2010) Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins. Expert Review of Hematology 3:5, pages 633-651.
Read now

Articles from other publishers (18)

Noa Granot, Andrew R. Rezvani, Barbara S. Pender, Barry E. Storer, Brenda M. Sandmaier, Rainer Storb & David G. Maloney. (2020) Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. Biology of Blood and Marrow Transplantation 26:10, pages 1811-1818.
Crossref
Marieke C. H. Hogenes, Suzanne van Dorp, Joyce van Kuik, Filipa R. P. Monteiro, Natalie ter Hoeve, Liane Guedes, Marijke R. van Dijk, Anton C. Martens & Roel A. de Weger. (2019) Modifying Graft-versus-Host Disease in a Humanized Mouse Model by Targeting Macrophages or B-Cells. Journal of Immunology Research 2019, pages 1-14.
Crossref
Ruben Rhoades & Sameh Gaballa. (2017) The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease. Biomedicines 5:4, pages 61.
Crossref
Attilio Olivieri, Daniela Massi, Andrea Bacigalupo & Anna Campanati. 2013. Blood and Marrow Transplantation Long-Term Management. Blood and Marrow Transplantation Long-Term Management 77 105 .
Craig L. Leonardi, Michael P. Heffernan & Jennifer G. Gill. 2013. Comprehensive Dermatologic Drug Therapy. Comprehensive Dermatologic Drug Therapy 333 341.e3 .
X Chen, C-H Chang, R Stein & D M Goldenberg. (2011) The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD. Bone Marrow Transplantation 47:7, pages 967-980.
Crossref
Jacopo Olivieri, Sabrina Coluzzi, Imma Attolico & Attilio Olivieri. (2011) Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside. The Scientific World JOURNAL 11, pages 1908-1931.
Crossref
Daniel Wolff, Michael Schleuning, Stephanie von Harsdorf, Ulrike Bacher, Armin Gerbitz, Michael Stadler, Francis Ayuk, Alexander Kiani, Rainer Schwerdtfeger, Georgia B. Vogelsang, Guido Kobbe, Martin Gramatzki, Anita Lawitschka, Mohamad Mohty, Steven Z. Pavletic, Hildegard Greinix & Ernst Holler. (2011) Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation 17:1, pages 1-17.
Crossref
Dimitrios Daoussis, Stamatis-Nick C. Liossis, Athanassios C. Tsamandas, Christina Kalogeropoulou, Alexandra Kazantzi, Panagiotis Korfiatis, Georgios Yiannopoulos & Andrew P. Andonopoulos. (2010) Is There a Role for B-cell Depletion as Therapy for Scleroderma? A Case Report and Review of the Literature. Seminars in Arthritis and Rheumatism 40:2, pages 127-136.
Crossref
David R. Carr & Michael P. Heffernan. (2010) Innovative Uses of Rituximab in Dermatology. Dermatologic Clinics 28:3, pages 547-557.
Crossref
Dimitrios Daoussis, Stamatis-Nick C. Liossis, Athanassios C. Tsamandas, Christina Kalogeropoulou, Alexandra Kazantzi, Chaido Sirinian, Maria Karampetsou, Georgios Yiannopoulos & Andrew P. Andonopoulos. (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49:2, pages 271-280.
Crossref
Alexander Shimabukuro-Vornhagen, Michael J. Hallek, Rainer F. Storb & Michael S. von Bergwelt-Baildon. (2009) The role of B cells in the pathogenesis of graft-versus-host disease. Blood 114:24, pages 4919-4927.
Crossref
Voravit Ratanatharathorn, Steven Pavletic & Joseph P. Uberti. (2009) Clinical applications of rituximab in allogeneic stem cell transplantation: Anti-tumor and immunomodulatory effects. Cancer Treatment Reviews 35:8, pages 653-661.
Crossref
Jill S Bates, Ashley Morris Engemann & Julia M Hammond. (2009) Clinical Utility of Rituximab in Chronic Graft-Versus-Host Disease. Annals of Pharmacotherapy 43:2, pages 316-321.
Crossref
Asha R. Patel, Daniele Avila, Harry L. Malech, Steven Z. Pavletic, Larry Yao & Edward W. Cowen. (2008) Rippled skin, fasciitis, and joint contractures. Journal of the American Academy of Dermatology 59:6, pages 1070-1074.
Crossref
M Mohty, N Marchetti, J El-Cheikh, C Faucher, S Fürst & D Blaise. (2008) Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplantation 41:10, pages 909-911.
Crossref
G. Guhl, B. Díaz-Ley & J. Fernández-Herrera. (2008) Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab. Actas Dermo-Sifiliográficas 99:1, pages 5-33.
Crossref
G. Guhl, B. Díaz-Ley & J. Fernández-Herrera. (2008) Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 2: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab, and Cetuximab. Actas Dermo-Sifiliográficas (English Edition) 99:1, pages 5-33.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.